Trial · NCT07904845
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Phase 1a: Number of Participants with Dose-Limiting Toxicities (DLTs) | Approximately 1 month | |
| Primary | Phase 1a: Number of Participants with Treatment-emergent Adverse Events (TEAEs), Treatment-related Adverse Events (TRAEs), and Serious Adverse Events (SAEs) | Up to approximately 9 months | |
| Primary | Phase 1b: Overall Response Rate (ORR) Assessed by the Investigator | Up to approximately 12 months | ORR is defined as the percentage of participants with a best overall response of partial response or better per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Secondary | Phase 1a: Overall Response Rate (ORR) Assessed by the Investigator | Up to approximately 9 months | ORR is defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. |
| Secondary | Phase 1a: Duration of Response (DOR) Assessed by the Investigator | Up to approximately 9 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Phase 1b: Duration of Response (DOR) Assessed by the Investigator | Up to approximately 12 months | DOR is defined as the time from the first determination of an objective response until the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Phase 1a: Disease Control Rate (DCR) Assessed by the Investigator | Up to approximately 9 months | DCR is defined as the percentage of participants with a BOR of a CR, PR, or stable disease (SD) per RECIST v1.1. |
| Secondary | Phase 1b: Disease Control Rate (DCR) at 12 Weeks Assessed by the Investigator | 12 Weeks | DCR at 12 weeks is defined as the percentage of participants with CR, PR, or SD per RECIST v1.1, and are alive and progression-free at Week 12. |
| Secondary | Phase 1b: Disease Control Rate (DCR) at 24 Weeks Assessed by the Investigator | 24 weeks | DCR at 24 weeks is defined as the percentage of participants with CR, PR, or SD according to RECIST v1.1, and are alive and progression-free at the Week 24. |
| Secondary | Phase 1b: Progression-free Survival (PFS) Assessed by the Investigator | Up to approximately 12 months | PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first. |
| Secondary | Area Under the Concentration Time Curve (AUC) of BON-C1393 | Up to approximately 3 months | |
| Secondary | Maximum Observed Plasma Concentration (Cmax) of BON-C1393 | Up to approximately 8 months | |
| Secondary | Time to Maximum Plasma Concentration (Tmax) of BON-C1393 | Up to approximately 8 months | |
| Secondary | Terminal Half-Life (t1/2) of BON-C1393 | Up to approximately 3 months | |
| Secondary | Plasma Concentrations of BON-C1393 | Up to approximately 12 months | |
| Secondary | Phase 1b: Number of Participants with Adverse Events | Up to approximately 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07904845/registered